AAAAAA

   
Results: 1-17 |
Results: 17
HYDROPHILICITY LIPOPHILICITY - RELEVANCE FOR THE PHARMACOLOGY AND CLINICAL EFFECTS OF HMG-COA REDUCTASE INHIBITORS/
Authors: HAMELIN BA TURGEON J
Citation: Ba. Hamelin et J. Turgeon, HYDROPHILICITY LIPOPHILICITY - RELEVANCE FOR THE PHARMACOLOGY AND CLINICAL EFFECTS OF HMG-COA REDUCTASE INHIBITORS/, Trends in pharmacological sciences, 19(1), 1998, pp. 26-37
THE EFFECT OF TIMING OF A STANDARD MEAL ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NOVEL ATYPICAL ANTIPSYCHOTIC AGENT ZIPRASIDONE
Authors: HAMELIN BA ALLARD S LAPLANTE L MICELI J WILNER KD TREMBLAY J LEBEL M
Citation: Ba. Hamelin et al., THE EFFECT OF TIMING OF A STANDARD MEAL ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NOVEL ATYPICAL ANTIPSYCHOTIC AGENT ZIPRASIDONE, Pharmacotherapy, 18(1), 1998, pp. 9-15
IN-VITRO CHARACTERIZATION OF CYTOCHROME-P450 2D6 INHIBITION BY CLASSIC HISTAMINE H-1 RECEPTOR ANTAGONISTS
Authors: HAMELIN BA BOUAYAD A DROLET B GRAVEL A TURGEON J
Citation: Ba. Hamelin et al., IN-VITRO CHARACTERIZATION OF CYTOCHROME-P450 2D6 INHIBITION BY CLASSIC HISTAMINE H-1 RECEPTOR ANTAGONISTS, Drug metabolism and disposition, 26(6), 1998, pp. 536-539
IMPROVED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR THE DETERMINATION OF PROCAINAMIDE AND ITS N-ACETYLATED METABOLITE IN PLASMA - APPLICATION TO A SINGLE-DOSE PHARMACOKINETIC STUDY
Authors: LESSARD E FORTIN A COQUET A BELANGER PM HAMELIN BA TURGEON J
Citation: E. Lessard et al., IMPROVED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR THE DETERMINATION OF PROCAINAMIDE AND ITS N-ACETYLATED METABOLITE IN PLASMA - APPLICATION TO A SINGLE-DOSE PHARMACOKINETIC STUDY, Journal of chromatographic science, 36(1), 1998, pp. 49-54
BLOCK OF THE RAPID COMPONENT OF THE DELAYED RECTIFIER POTASSIUM CURRENT BY THE PROKINETIC AGENT CISAPRIDE UNDERLIES DRUG-RELATED LENGTHENING OF THE QT INTERVAL
Authors: DROLET B KHALIFA M DALEAU P HAMELIN BA TURGEON J
Citation: B. Drolet et al., BLOCK OF THE RAPID COMPONENT OF THE DELAYED RECTIFIER POTASSIUM CURRENT BY THE PROKINETIC AGENT CISAPRIDE UNDERLIES DRUG-RELATED LENGTHENING OF THE QT INTERVAL, Circulation, 97(2), 1998, pp. 204-210
ROLE OF CYP2D6 IN THE N-HYDROXYLATION OF PROCAINAMIDE
Authors: LESSARD E FORTIN A BELANGER PM BEAUNE P HAMELIN BA TURGEON J
Citation: E. Lessard et al., ROLE OF CYP2D6 IN THE N-HYDROXYLATION OF PROCAINAMIDE, Pharmacogenetics, 7(5), 1997, pp. 381-390
BLOCK OF I-KS BY THE DIURETIC AGENT INDAPAMIDE MODULATES CARDIAC ELECTROPHYSIOLOGICAL EFFECTS OF THE CLASS-III ANTIARRHYTHMIC DRUG DL-SOTALOL
Authors: FISET C DROLET B HAMELIN BA TURGEON J
Citation: C. Fiset et al., BLOCK OF I-KS BY THE DIURETIC AGENT INDAPAMIDE MODULATES CARDIAC ELECTROPHYSIOLOGICAL EFFECTS OF THE CLASS-III ANTIARRHYTHMIC DRUG DL-SOTALOL, The Journal of pharmacology and experimental therapeutics, 283(1), 1997, pp. 148-156
PHARMACODYNAMIC (PD) INTERACTION OF DIPHENHYDRAMINE (DPH) AND METOPROLOL (MET)
Authors: BOUAYAD A DESGAGNES P JOBIN J TURGEON J HAMELIN BA
Citation: A. Bouayad et al., PHARMACODYNAMIC (PD) INTERACTION OF DIPHENHYDRAMINE (DPH) AND METOPROLOL (MET), Clinical pharmacology and therapeutics, 61(2), 1997, pp. 2-2
MEXILETINE (MEX) AS A PROBE DRUG TO DETERMINE CYP2D6 PHENOTYPE
Authors: LABBE L HAMELIN BA FISET C LEFEZ C OHARA G GILBERT M TURGEON J
Citation: L. Labbe et al., MEXILETINE (MEX) AS A PROBE DRUG TO DETERMINE CYP2D6 PHENOTYPE, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 28-28
IN-VITRO INHIBITION OF CYP3A4 BY HISTAMINE H1 RECEPTOR ANTAGONISTS
Authors: HAMELIN BA GAUVIN C TURGEON J
Citation: Ba. Hamelin et al., IN-VITRO INHIBITION OF CYP3A4 BY HISTAMINE H1 RECEPTOR ANTAGONISTS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 30-30
THE DISPOSITION OF FLUOXETINE BUT NOT SERTRALINE IS ALTERED IN POOR METABOLIZERS OF DEBRISOQUIN
Authors: HAMELIN BA TURGEON J VALLEE F BELANGER PM PAQUET F LEBEL M
Citation: Ba. Hamelin et al., THE DISPOSITION OF FLUOXETINE BUT NOT SERTRALINE IS ALTERED IN POOR METABOLIZERS OF DEBRISOQUIN, Clinical pharmacology and therapeutics, 60(5), 1996, pp. 512-521
ROLE OF CYP2D6 IN THE DEMETHYLATION OF FLUOXETINE IN-VIVO
Authors: HAMELIN BA TURGEON J VALLEE F BELANGER PM PAQUET F LEBEL M
Citation: Ba. Hamelin et al., ROLE OF CYP2D6 IN THE DEMETHYLATION OF FLUOXETINE IN-VIVO, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 33-33
CLASSIC ANTIHISTAMINES INHIBIT CYP2D6 IN-VITRO
Authors: HAMELIN BA GRAVEL A TURGEON J
Citation: Ba. Hamelin et al., CLASSIC ANTIHISTAMINES INHIBIT CYP2D6 IN-VITRO, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 53-53
DISPOSITION OF PROCAINAMIDE IN SUBJECTS WITH LOW OR HIGH CYP2D6 ACTIVITY
Authors: LESSARD E BELANGER PM HAMELIN BA TURGEON J
Citation: E. Lessard et al., DISPOSITION OF PROCAINAMIDE IN SUBJECTS WITH LOW OR HIGH CYP2D6 ACTIVITY, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 91-91
CAFFEINE METABOLISM IN CYSTIC-FIBROSIS - ENHANCED XANTHINE-OXIDASE ACTIVITY
Authors: HAMELIN BA XU KY VALLE F MANSEAU L RICHER M LEBEL M
Citation: Ba. Hamelin et al., CAFFEINE METABOLISM IN CYSTIC-FIBROSIS - ENHANCED XANTHINE-OXIDASE ACTIVITY, Clinical pharmacology and therapeutics, 56(5), 1994, pp. 521-529
PHARMACOGENETICS IN CHILDREN WITH CYSTIC-FIBROSIS
Authors: HAMELIN BA XU KY VALLEE F MANSEAU L RICHER M LEBEL M
Citation: Ba. Hamelin et al., PHARMACOGENETICS IN CHILDREN WITH CYSTIC-FIBROSIS, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 172-172
CEFEPIME PHARMACOKINETICS IN CYSTIC-FIBROSIS
Authors: HAMELIN BA MOORE N KNUPP CA RUEL M VALLEE F LEBEL M
Citation: Ba. Hamelin et al., CEFEPIME PHARMACOKINETICS IN CYSTIC-FIBROSIS, Pharmacotherapy, 13(5), 1993, pp. 465-470
Risultati: 1-17 |